ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

NCT07673627 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

AChR-Ab Seropositive Generalized Myasthenia Gravis
Myasthenia Gravis (MG)
MG - Myasthenia Gravis
gMG

Interventions

BIOLOGICAL: Empasiprubart IV
OTHER: Placebo IV
COMBINATION_PRODUCT: Efgartigimod PH20 SC PFS

Sponsor

argenx